[Acromegaly and it's cardiovascular implications].

Centro Médico ABC, Campus Observatorio, Servicio de Endocrinología, Ciudad de México, México. Universidad Anáhuac, Facultad de Medicina, Servicio Rotatorio de Pregrado, Ciudad de México, México. Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades Dr. Bernardo Sepúlveda Gutiérrez, Unidad de Investigación Médica en Enfermedades Endócrinas, Ciudad de México, México.

Revista medica del Instituto Mexicano del Seguro Social. 2021;(1):73-80

Abstract

Acromegaly is a chronic and slowly progressive disease that results from the hypersecretion of growth hormone (GH) and consequently insulin-like growth factor type 1 (IGF-1), due to a GH-secreting pituitary adenoma in 95-98% of cases. There are several complications or co-morbidities associated with acromegaly, the most frequent being cardiovascular, metabolic and neoplastic. The cardiovascular complications of acromegaly go from arterial hypertension to a peculiar form of cardiomyopathy and are the result of the long-standing exposure to high GH and IGF-1 levels. The pathophysiology of these complications is complex and includes an increased tubular reabsorption of sodium and the direct effects of GH and IGF-1 on the endothelium and the cardiac tissue itself. Frequently, the cardiovascular comorbidities of acromegaly occur concomitantly with metabolic complications such as diabetes and respiratory abnormalities such as the sleep apnea syndrome. In this brief review we analyze the pathophysiology, the clinical manifestations and the management of the cardiovascular complications of acromegaly.

Methodological quality

Publication Type : Review

Metadata